Janssen Pharmaceuticals, Inc. has entered a results-based contract for long-acting injectable schizophrenia medicines (LAIs) with the Oklahoma Health Care Authority (OHCA), which manages Oklahoma’s Medicaid plan, SoonerCare.

The agreement is focused on enabling the use of INVEGA SUSTENNA (paliperidone palmitate) and INVEGA TRINZA (paliperidone palmitate) earlier in treatment of adults with schizophrenia, in an effort to improve patient care and reduce medical expenses.

A comparative effectiveness study found that the long-acting treatment INVEGA SUSTENNA demonstrated superiority versus a group of commonly prescribed oral treatments in delaying time to relapse.

“With health care costs a concern nationwide, we’re excited to be working with Oklahoma to expand patient access to these transformational medicines that can play a role in making public programs more sustainable,” said Blasine Penkowski, chief strategic customer officer, Johnson & Johnson Health Care Systems Inc. “We’re pleased that Oklahoma sees their clinical and economic value and their potential to reduce costs by improving care for patients with schizophrenia.”